Curanex Pharmaceuticals Inc
CURX0.375USD
-0.020-5.14%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
10.62MMarket Cap
LossP/E TTM
More Details of Curanex Pharmaceuticals Inc Company
Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company. The Company is engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties that act via multiple targets and mechanisms. Its drug development pipelines encompass six various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, and gout. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis, aiming to address limitations of current treatments. The Company's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).
Curanex Pharmaceuticals Inc Info
Ticker SymbolCURX
Company nameCuranex Pharmaceuticals Inc
IPO dateAug 26, 2025
CEOLiu (Jun)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endAug 26
Address2 Jericho Plaza
CityJERICHO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code11753
Phone17186736078
Websitehttps://www.curanexpharma.com/
Ticker SymbolCURX
IPO dateAug 26, 2025
CEOLiu (Jun)
Company Executives of Curanex Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jun Liu
Mr. Jun Liu
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
7.99M
--
Ms. Dian Ying Jing
Ms. Dian Ying Jing
Secretary, Director
Secretary, Director
3.25M
--
Mr. Xiaohui Hao
Mr. Xiaohui Hao
Independent Director
Independent Director
--
--
Dr. Liqin Xie
Dr. Liqin Xie
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Yong Yan, Ph.D.
Mr. Yong Yan, Ph.D.
Independent Director
Independent Director
--
--
Ms. Huijuan Zhong
Ms. Huijuan Zhong
Chief Science Officer
Chief Science Officer
--
--
Mr. Ning Zhang, Ph.D.
Mr. Ning Zhang, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Yanming Du, Ph.D.
Mr. Yanming Du, Ph.D.
Independent Director
Independent Director
--
--
Ms. Haiyan Yang
Ms. Haiyan Yang
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jun Liu
Mr. Jun Liu
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
7.99M
--
Ms. Dian Ying Jing
Ms. Dian Ying Jing
Secretary, Director
Secretary, Director
3.25M
--
Mr. Xiaohui Hao
Mr. Xiaohui Hao
Independent Director
Independent Director
--
--
Dr. Liqin Xie
Dr. Liqin Xie
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Yong Yan, Ph.D.
Mr. Yong Yan, Ph.D.
Independent Director
Independent Director
--
--
Ms. Huijuan Zhong
Ms. Huijuan Zhong
Chief Science Officer
Chief Science Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Liu (Jun)
28.19%
Liu (Chang)
28.17%
Jing (Dian Ying)
11.46%
Citadel Advisors LLC
0.23%
UBS Financial Services, Inc.
0.16%
Other
31.80%
Shareholders
Shareholders
Proportion
Liu (Jun)
28.19%
Liu (Chang)
28.17%
Jing (Dian Ying)
11.46%
Citadel Advisors LLC
0.23%
UBS Financial Services, Inc.
0.16%
Other
31.80%
Shareholder Types
Shareholders
Proportion
Individual Investor
67.82%
Hedge Fund
0.41%
Investment Advisor
0.33%
Research Firm
0.14%
Bank and Trust
0.07%
Investment Advisor/Hedge Fund
0.07%
Other
31.18%
Institutional Shareholding
Updated: Fri, Sep 12
Updated: Fri, Sep 12
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1
18.67K
0.07%
+18.67K
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Liu (Jun)
7.99M
28.19%
+7.99M
--
Aug 26, 2025
Liu (Chang)
7.98M
28.17%
+7.98M
--
Aug 26, 2025
Jing (Dian Ying)
3.25M
11.46%
+3.25M
--
Aug 26, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Curanex Pharmaceuticals Inc?
The top five shareholders of Curanex Pharmaceuticals Inc are:
Liu (Jun) holds 7.99M shares, accounting for 28.19% of the total shares.
Liu (Chang) holds 7.98M shares, accounting for 28.17% of the total shares.
Jing (Dian Ying) holds 3.25M shares, accounting for 11.46% of the total shares.
Liu (Jun) holds 7.99M shares, accounting for 28.19% of the total shares.
Liu (Chang) holds 7.98M shares, accounting for 28.17% of the total shares.
Jing (Dian Ying) holds 3.25M shares, accounting for 11.46% of the total shares.
What are the top three shareholder types of Curanex Pharmaceuticals Inc?
The top three shareholder types of Curanex Pharmaceuticals Inc are:
Liu (Jun)
Liu (Chang)
Jing (Dian Ying)
Liu (Jun)
Liu (Chang)
Jing (Dian Ying)
How many institutions hold shares of Curanex Pharmaceuticals Inc (CURX)?
As of 2025Q3, 1 institutions hold shares of Curanex Pharmaceuticals Inc, with a combined market value of approximately 18.67K, accounting for 0.07% of the total shares. Compared to --, institutional shareholding has increased by --.
What is the biggest source of revenue for Curanex Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Curanex Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
